Migraine is a debilitating , 2^nd common cause of chronic  headache   affecting 15% women and 6% men annually. Migraine with aura (MA) and migraine without aura are 2 subtypes. 25 % patients experience aura preceding the onset of pain. Aura  is a transient disturbance in visual, sensory, language, or motor function. Pathophysiology of migraine includes genetic, environmental triggers, cerebral ischemia followed by stimulation of  trigeminovascular system which in turn results in the symptoms. Acute attack of mild migraine can be managed by oral agents, but the  average efficacy rate is only 50 – 70%. Patients with increased  frequency of migraine attacks or unresponsive or poorly responsive to currently prescribed  standard treatment, are started on long term prophylaxis and often expensive with side effects.Pyridoxine is a vitamin of B complex group involved in metabolism reactions of the nervous system. Previous studies were done with combination of B complex vitamins, or  Pyridoxine  as montherapy for a period of 12 weeks, found to have beneficial effects on severity and frequency of migraine attacks, but the participants were not followed up after stopping pyridoxine supplementation . Hence this study is  planned to supplement  pyridoxine in patients uncontrolled with standard prophylaxis to assess the effect of pyridoxine supplementation as an adjuvant  for reduction of symptoms frequency for a period of 6 months and recurrence during the  follow up period for 3 months after stopping pyridoxine, while standard therapy is continued.